Skip to main content
ResearchTreatments

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

By September 6, 2021November 7th, 2021No Comments

*April 2021*

Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated patients.

Dr. Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors. Watch his presentation here.